Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we answer these fundamental questions through investigation of the genetic and epigenetic pathways that control the origin of ABCB1 (MDR1) gene activation with acquired multidrug resistance in drug-sensitive human sarcoma (MES-SA cells).
|
16230402 |
2005 |
Sarcoma
|
0.100 |
GeneticVariation
|
group |
LHGDN |
We investigated MDR1 activation in MDR variants of a human sarcoma line, some of which express a mutant MDR1, which facilitated the study of allelic gene expression.
|
12112526 |
2002 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Due to these favorable characteristics sarcoma is an attractive target to test the efficacy of MDR1 gene therapy in a clinical setting.
|
12426490 |
2002 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We investigated MDR1 activation in MDR variants of a human sarcoma line, some of which express a mutant MDR1, which facilitated the study of allelic gene expression.
|
12112526 |
2002 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In six sarcomas with mdr1 mRNA expression, five were resistant against doxorubicin and cross-resistant against several other drugs, whereas from eight sarcomas, which lacked detectable mdr1 mRNA, seven were sensitive to doxorubicin and other drugs.
|
10473106 |
1999 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor specimens prior to and following neoadjuvant chemotherapy from 29 cases of high grade soft tissue sarcoma were analyzed with 2 monoclonal antibodies (C494 and JSB-1) that recognize different epitopes of P-glycoprotein.
|
10491523 |
1999 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By using human multidrug resistant sarcoma cell lines as controls, we analyzed P-glycoprotein expression in 34 primary and in 23 relapsed soft tissue sarcomas of the extremities.
|
8862015 |
1996 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this review, an attempt is made to summarise the accuracy of the measurement of MDR1 expression for use in prognosis, as well as in decisions on chemotherapeutic treatment of sarcomas.
|
8695249 |
1996 |
Sarcoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, RNA dot-blot analysis with digoxigenin-labeled RNA probe and immunohistochemistry with JSB-1 and C-219 antibodies for P-glycoprotein were employed in 34 and 37 samples in soft tissue sarcomas, respectively.
|
8727096 |
1996 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further studies on drug resistance mechanisms and the role of MDR1 expression in sarcomas have been reported.
|
7803538 |
1994 |
Sarcoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Expression of the mdr1 gene in bone and soft tissue sarcomas of adult patients.
|
7904171 |
1993 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This study confirms that MDR1 overexpression occurs in human sarcomas but is not the principal mechanism of drug-resistance.
|
7903154 |
1993 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness.
|
1606072 |
1992 |
Sarcoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Units of mdr1 expression were defined by reference to drug-sensitive human sarcoma and K562 leukemia cell lines (1 U) and the highly resistant doxorubicin selected leukemia cells K562/R7 (50 U).
|
1859877 |
1991 |